Nov 7, 2019 8:00 am EST SCYNEXIS Reports Positive Top-Line Results from First Phase 3 Registration Study of Oral Ibrexafungerp in Vulvovaginal Candidiasis (VANISH-303)
Oct 31, 2019 8:30 am EDT SCYNEXIS Announces Oral Presentation of Data from Ibrexafungerp Phase 2b DOVE Study at the 3rd ISIDOG Congress
Oct 24, 2019 8:30 am EDT SCYNEXIS Expands FURI Protocol to a Broader Range of Refractory Serious Fungal Infections, Building on Ibrexafungerp's Positive Data and Favorable Toxicology Profile Observed to Date
Oct 10, 2019 8:30 am EDT SCYNEXIS to Strengthen its Balance Sheet with Non-Dilutive Funding Through the New Jersey Economic Development Authority Net Operating Loss and R&D Tax Credits Program
Oct 2, 2019 8:30 am EDT SCYNEXIS to Present Data at IDWeek 2019 and the 9th Congress on Trends in Medical Mycology (TIMM-9) Highlighting Scientific and Clinical Evidence of Ibrexafungerp's Activity Against Resistant Fungal Pathogens, Including Candida auris
Sep 18, 2019 8:30 am EDT SCYNEXIS Completes Last-Patient/Last-Visit Ahead of Schedule in the First Phase 3 Study (VANISH 303) of Oral Ibrexafungerp for the Treatment of Vulvovaginal Candidiasis (VVC)
Aug 7, 2019 4:15 pm EDT SCYNEXIS Reports Second Quarter 2019 Financial Results and Provides Company Update
Jul 31, 2019 8:00 am EDT SCYNEXIS, Inc. to Present at the 39th Annual Canaccord Genuity Global Growth Conference
Jul 24, 2019 8:00 am EDT SCYNEXIS Announces Special Protocol Assessment (SPA) Agreement with FDA for Phase 3 Study Evaluating Oral Ibrexafungerp for the Prevention of Recurrent Vulvovaginal Candidiasis (VVC) (CANDLE Study)
